Vera Therapeutics, Inc. VERA
- TRUTAKNA — IgA Nephropathy Approved
- TRUTAKNA — Primary Membranous Nephropathy Phase 2
- TRUTAKNA — Focal Segmental Glomerulosclerosis Phase 2
- TRUTAKNA — Minimal Change Disease Phase 2
TACI (1 companies · 4 programs)
Companies with an active program directed at TACI.